This study enrolled 19 volunteers with an average age of 65 in a concurrent training program combining both aerobic and resistance exercise. Participants were divided into two groups: one training three times per week, the other five times per week. Both groups followed the same type of high-effort training protocol. The study measured BDNF, VO2max, and muscular strength before and after the intervention to determine whether training frequency was a meaningful variable in outcomes for older adults.

Both groups showed significant improvements in serum BDNF, VO2max, and muscular strength. The critical finding: there was no statistically significant difference between the three-day and five-day groups on any outcome measure. Frequency did not predict results. What predicted results was the consistent application of challenging, high-effort training — regardless of how many days per week that training occurred. BDNF increases were meaningful in both groups, reinforcing that older adults retain robust neuroplastic response to exercise.

For men over 50 who feel they don't have time to train five or six days a week, this study is directly reassuring. Three days per week of quality, high-intensity training produced the same gains in brain health, cardiovascular fitness, and muscle strength as five days per week. This aligns with the sprint training philosophy underpinning this site: brief, intense, infrequent sessions can produce exceptional results. The key variable is not time logged — it is quality of effort in each session.

Why This Matters for Men 50+

One of the most common reasons men don't start sprinting is the belief that they don't have enough time. This study provides direct evidence that three high-quality training sessions per week produce the same improvements in BDNF, VO2max, and strength as five sessions in adults averaging age 65. You don't need to train every day. You need to train hard on the days you do.

Source & Attribution

Authors: Matos F, et al.
Journal: Frontiers in Aging Neuroscience, Volume 14, Article 791698 (2022)
DOI: 10.3389/fnagi.2022.791698
PubMed ID: 35360220  |  PMC: PMC8940272

Published under the Creative Commons Attribution License (CC BY). Use, distribution, and reproduction permitted in any forum, provided the original authors and source are credited in accordance with accepted academic practice.

Read Full Study Download PDF